Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Transient decrease of serum iron after acute erythropoietin treatment contributes to hepcidin inhibition by ERFE in mice.

Artuso I, Pettinato M, Nai A, Pagani A, Sardo U, Billoré B, Lidonnici MR, Bennett C, Mandelli G, Pasricha SR, Ferrari G, Camaschella C, Kautz L, Silvestri L.

Haematologica. 2018 Sep 28. pii: haematol.2018.199810. doi: 10.3324/haematol.2018.199810. [Epub ahead of print] No abstract available.

2.

Erythroferrone inhibits the induction of hepcidin by BMP6.

Arezes J, Foy N, McHugh K, Sawant A, Quinkert D, Terraube V, Brinth A, Tam M, LaVallie ER, Taylor S, Armitage AE, Pasricha SR, Cunningham O, Lambert M, Draper SJ, Jasuja R, Drakesmith H.

Blood. 2018 Oct 4;132(14):1473-1477. doi: 10.1182/blood-2018-06-857995. Epub 2018 Aug 10.

3.

Limiting hepatic Bmp-Smad signaling by matriptase-2 is required for erythropoietin-mediated hepcidin suppression in mice.

Nai A, Rubio A, Campanella A, Gourbeyre O, Artuso I, Bordini J, Gineste A, Latour C, Besson-Fournier C, Lin HY, Coppin H, Roth MP, Camaschella C, Silvestri L, Meynard D.

Blood. 2016 May 12;127(19):2327-36. doi: 10.1182/blood-2015-11-681494. Epub 2016 Jan 11.

4.

Erythropoietic regulators of iron metabolism.

Ganz T.

Free Radic Biol Med. 2018 Jul 5. pii: S0891-5849(18)31188-2. doi: 10.1016/j.freeradbiomed.2018.07.003. [Epub ahead of print]

PMID:
29981834
5.

Erythroferrone is not required for the glucoregulatory and hematologic effects of chronic erythropoietin treatment in mice.

Coffey R, Sardo U, Kautz L, Gabayan V, Nemeth E, Ganz T.

Physiol Rep. 2018 Sep;6(19):e13890. doi: 10.14814/phy2.13890.

6.

Erythroferrone contributes to recovery from anemia of inflammation.

Kautz L, Jung G, Nemeth E, Ganz T.

Blood. 2014 Oct 16;124(16):2569-74. doi: 10.1182/blood-2014-06-584607. Epub 2014 Sep 5.

7.

Associations among Erythroferrone and Biomarkers of Erythropoiesis and Iron Metabolism, and Treatment with Long-Term Erythropoiesis-Stimulating Agents in Patients on Hemodialysis.

Honda H, Kobayashi Y, Onuma S, Shibagaki K, Yuza T, Hirao K, Yamamoto T, Tomosugi N, Shibata T.

PLoS One. 2016 Mar 15;11(3):e0151601. doi: 10.1371/journal.pone.0151601. eCollection 2016.

8.

Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of β-thalassemia.

Kautz L, Jung G, Du X, Gabayan V, Chapman J, Nasoff M, Nemeth E, Ganz T.

Blood. 2015 Oct 22;126(17):2031-7. doi: 10.1182/blood-2015-07-658419. Epub 2015 Aug 14.

9.

Immunoassay for human serum erythroferrone.

Ganz T, Jung G, Naeim A, Ginzburg Y, Pakbaz Z, Walter PB, Kautz L, Nemeth E.

Blood. 2017 Sep 7;130(10):1243-1246. doi: 10.1182/blood-2017-04-777987. Epub 2017 Jul 24.

10.

EPO-dependent induction of erythroferrone drives hepcidin suppression and systematic iron absorption under phenylhydrazine-induced hemolytic anemia.

Jiang X, Gao M, Chen Y, Liu J, Qi S, Ma J, Zhang Z, Xu Y.

Blood Cells Mol Dis. 2016 May;58:45-51. doi: 10.1016/j.bcmd.2016.02.005. Epub 2016 Feb 19.

PMID:
27067488
11.

Erythropoietin administration increases splenic erythroferrone protein content and liver TMPRSS6 protein content in rats.

Gurieva I, Frýdlová J, Rychtarčíková Z, Vokurka M, Truksa J, Krijt J.

Blood Cells Mol Dis. 2017 May;64:1-7. doi: 10.1016/j.bcmd.2017.02.007. Epub 2017 Feb 28.

PMID:
28282554
12.

Smad1/5 is required for erythropoietin-mediated suppression of hepcidin in mice.

Wang CY, Core AB, Canali S, Zumbrennen-Bullough KB, Ozer S, Umans L, Zwijsen A, Babitt JL.

Blood. 2017 Jul 6;130(1):73-83. doi: 10.1182/blood-2016-12-759423. Epub 2017 Apr 24.

13.

Identification of erythroferrone as an erythroid regulator of iron metabolism.

Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T.

Nat Genet. 2014 Jul;46(7):678-84. doi: 10.1038/ng.2996. Epub 2014 Jun 1.

14.

The hepcidin-25/erythroferrone ratio predicts improvement of anemia in hemodialysis patients treated with ferric citrate hydrate.

Hara M, Nakamura Y, Suzuki H, Asao R, Nakamura M, Nishida K, Kenmotsu S, Inagaki M, Tsuji M, Kiuchi Y, Ohsawa I, Goto Y, Gotoh H.

Nephrology (Carlton). 2018 Sep 21. doi: 10.1111/nep.13495. [Epub ahead of print]

PMID:
30239062
15.

Plasma hepcidin in early-stage breast cancer patients: no relationship with interleukin-6, erythropoietin and erythroferrone.

Ciniselli CM, De Bortoli M, Taverna E, Varinelli L, Pizzamiglio S, Veneroni S, Bonini C, Orlandi R, Verderio P, Bongarzone I.

Expert Rev Proteomics. 2015;12(6):695-701. doi: 10.1586/14789450.2015.1099436. Epub 2015 Oct 23.

PMID:
26496240
16.

Characterization of Putative Erythroid Regulators of Hepcidin in Mouse Models of Anemia.

Mirciov CS, Wilkins SJ, Dunn LA, Anderson GJ, Frazer DM.

PLoS One. 2017 Jan 30;12(1):e0171054. doi: 10.1371/journal.pone.0171054. eCollection 2017.

17.

Erythropoietin's inhibiting impact on hepcidin expression occurs indirectly.

Gammella E, Diaz V, Recalcati S, Buratti P, Samaja M, Dey S, Noguchi CT, Gassmann M, Cairo G.

Am J Physiol Regul Integr Comp Physiol. 2015 Feb 15;308(4):R330-5. doi: 10.1152/ajpregu.00410.2014. Epub 2014 Dec 17.

18.

Hepcidin as a potential biomarker for blood doping.

Leuenberger N, Bulla E, Salamin O, Nicoli R, Robinson N, Baume N, Saugy M.

Drug Test Anal. 2017 Jul;9(7):1093-1097. doi: 10.1002/dta.2122. Epub 2016 Nov 18.

PMID:
27758046
19.

Acute acetaminophen intoxication leads to hepatic iron loading by decreased hepcidin synthesis.

van Swelm RP, Laarakkers CM, Blous L, Peters JG, Blaney Davidson EN, van der Kraan PM, Swinkels DW, Masereeuw R, Russel FG.

Toxicol Sci. 2012 Sep;129(1):225-33. doi: 10.1093/toxsci/kfs176. Epub 2012 May 18.

PMID:
22610607
20.

Erythroferrone contributes to hepcidin repression in a mouse model of malarial anemia.

Latour C, Wlodarczyk MF, Jung G, Gineste A, Blanchard N, Ganz T, Roth MP, Coppin H, Kautz L.

Haematologica. 2017 Jan;102(1):60-68. doi: 10.3324/haematol.2016.150227. Epub 2016 Sep 22.

Supplemental Content

Support Center